Carvedilol for Prevention of Esophageal Varices Progression
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol.
But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis
B patients was unclear.